U.S. Platent and Transformack Offers, U.S. Patent and Transformack Offers (U.S. Patent and Transformack Offers) and Transformack Offers (U.S. Patent a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10601064				
Filing Date		2003-06-20				
First Named Inventor Robe		rt A. Baydo				
Art Unit		1761				
Examiner Name	Adep	eju Omolola Pearse				
Attorney Docket Numb	er	085516-9010 US00				

			Remove			
		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	2982234		1961-05-02	Ackley et al.	
	2	5409715		1995-04-25	Meyers	
	3 6067996			2000-05-30	Weber et al.	
	4	6267997		2001-07-31	Ream et al.	
	5	6607744		2003-08-19	Ribi	
	6	6616958		2003-09-09	Stewart	
	7 6652897		2003-11-25	Stewart		
	8	6866863		2005-03-15	Ribi	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Ī	Application Number		10601064		
	Filing Date		2003-06-20		
	First Named Inventor	Rober	rt A. Baydo		
	Art Unit		1761		
	Examiner Name Adep		eju Omolola Pearse		
	Attorney Docket Numb	or	085516,9010 US00		

	9 6893671 2005-05-17		Ben-Yoseph et al.								
If you wis	h to a	dd additional U.S. Paten			ease click the Add button.		Add				
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where les or Relevant			
1 20020114963		20020114863		2002-08-22	Ream et al.						
2 20030037700 3 20030103905		20030037700		2003-02-27	Leu et al.						
		20030103905		2003-06-05	Ribi						
	4	20030161913		2003-08-28	Slewart						
	5	20030198720		2003-10-23	Stewart						
	6 20040050289 7 20040086603			2004-03-18	Russell et al.						
				2004-05-06	Shastry et al.						
8 20040120991			2004-06-24	Gardner et al.							

Application Number Filing Date 2003-06-20 INFORMATION DISCLOSURE First Named Inventor Robert A. Baydo STATEMENT BY APPLICANT Art Unit 1761 ( Not for submission under 37 CFR 1.99) Examiner Name Adepeiu Omolola Pearse 085516-9010 US00 Attorney Docket Number

10601064

9	20040170725	2004-09-02	Begleiter	
10	20040213875	2004-10-28	Stewart	
11	20050003056	2005-01-06	Romanach et al.	
12	20050058753	2005-03-17	Romanach et al.	
13	20050058749	2005-03-17	Romanach et al.	
14	20050061184	2005-03-24	Russell et al.	
15	20050069612	2005-03-31	Romanach et al.	
16	20050157148	2005-07-21	Baker et al.	
17	20050163898	2005-07-28	Romanach et al.	
18	20050255205	2005-11-17	Baydo et al.	
19	20060034984	2006-02-16	Baydo et al.	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Filing Dat Art Unit Examiner

Application Number		10601064		
Filing Date		2003-06-20		
First Named Inventor Rober		rt A. Baydo		
Art Unit		1761		
Examiner Name Adep		eju Omolola Pearse		
Attomory Docket Number		095546 0040 LICOO		

	20	20060038866		2006-02	2-23	Wen et al.				
	21	20060110551		2006-05	5-25	Shastry et al.				
	22	20060182856		2006-08	3-17	Omelaz				
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	n citatio	n information p	olease click the Add	d butto	n. Add	
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>	y i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	те
	1	660750	СН			1987-06-15	Dr. Karl Thomae et	al.		
	2	662358	СН			1978-12-22	Franz Buttner AG e	t al.		
	3	63063363	JP			1988-03-19	Ikeda Touka Kogyo	KK		
	4	02/085995	wo			2002-10-31	Decopac, Inc. et al.			
	5	2004/003089	wo			2004-01-08	Mars Inc.			
	6	2004/012518	wo			2004-02-12	Mars Inc.			

#### 

2004-09-23

Mars Inc.

wo

	10	2005/027655	wo		2005-03-31	Procter & Gamble Co. et		П		
		2000027000			2000000	al.		Ц		
	11	2006/023615	wo		2006-03-02	Procter & Gamble Co. et al.				
	12	2006/086780	wo		2006-08-17	Mars Inc.				
	13	2006/086781	wo		2006-08-17	Mars Inc.				
	14	2006/121936	wo		2006-11-16	Dimatix, Inc.				
If you wisl	h to ac	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add button	Add			
			NON-PATEN	IT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (lobol, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	Database WP1 Week 2001, Derwent Publications Ltd., London, GB, AN 2001-409143 (XP002349407), LI, Y, "High grade exible paint mimeograph," & CN 1198 346 A (LI Y) (8/3/1997) abstract									
If you wish	h to ac	ld additional non-paten	t literature docur	ment cit	ation informati	on please click the Add b	utton Add			

7 2004/080191

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10601064
iling Date		2003-06-20
irst Named Inventor Rober		rt A. Baydo
urt Unit		1761
xaminer Name	Adep	eju Omolola Pearse
ttomey Docket Numb	or	085516-9010 US00

EXAMINER SIGNATURE											
Examiner Signature		Date Considered									
	reference considered, whether or not citation is in conformation and not considered. Include copy of this form with										

F

E

See Kint Codes of USPTO Patent Documents at sever USPTO GOV; or MPEP 901.04. Enter of tice that issued the document, by the two-letter of the Spandard ST3.) For Explaneses patent documents, the included on the year of the import on precise the serial running the Emplorer name precise the serial running the plant document.

\*\*Incl of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible. \*\*Applicant is to place a check mark here if Emploit inauguages translation is situation.\*\*

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10601064		
Filing Date		2003-06-20		
First Named Inventor Rober		rt A. Baydo		
Art Unit		1761		
Examiner Name Adept		eju Omolola Pearse		
Attorney Docket Numb	er	085516-9010 US00		

#### CERTIFICATION STATEMENT

Diagra can	37	CFR .	97	and 1	QR to	make the	annonnista	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gregory J Hartwig/	Date (YYYY-MM-DD)	2006-12-19
Name/Print	Grenny J Hartwin	Registration Number	46761

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.